GNH USA

Europe — EMA

Meropenem Anfarm (Meropenem Anhydrous)

GNH USA supplies Meropenem Anfarm (Meropenem), a carbapenem antibiotic for severe intra‑abdominal infections, urinary tract infections, pneumonia, meningitis

Meropenem Anhydrous

Request sourcing

1
Pack/s

What is Meropenem Anhydrous?

Meropenem, the active ingredient in Meropenem Anfarm, is a carbapenem antibiotic presented as an injection for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, nosocomial pneumonia, meningitis, and severe sepsis in hospitalized patients.

GNH USA supplies Meropenem Anfarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

What is Meropenem Anhydrous used for?

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections that require intravenous therapy.

Complicated intra‑abdominal infections: provides bactericidal activity to eradicate the infection. Complicated urinary tract infections: eliminates resistant uropathogens causing severe UTIs. Nosocomial pneumonia: treats hospital‑acquired lung infections resistant to other antibiotics. Meningitis: penetrates the cerebrospinal fluid to eradicate causative bacteria. Severe sepsis and septic shock: offers rapid bacterial clearance in critically ill patients.

What are the side effects of Meropenem Anhydrous?

Adverse reactions may occur with meropenem therapy and are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Rash or pruritus - Headache - Elevated liver enzymes - Infusion site erythema or phlebitis

Serious or Rare Side Effects: - Seizures, especially in patients with renal impairment or CNS disorders - Clostridioides difficile‑associated colitis - Anaphylaxis or severe hypersensitivity reactions - Severe neutropenia or leukopenia - Renal toxicity or acute kidney injury - Hypersensitivity leading to Stevens‑Johnson syndrome or toxic epidermal necrolysis

What precautions apply to Meropenem Anhydrous?

Meropenem should be used with caution in specific clinical situations and patient populations.

Renal function: assess creatinine clearance and adjust dose if needed. Hepatic impairment: monitor liver enzymes during therapy. Seizure risk: avoid in patients with a history of seizures or CNS disorders. Valproic acid co‑administration: may increase neurotoxicity; monitor closely. Pregnancy: safety category unknown; weigh benefits against potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Meropenem Anhydrous interact with?

Meropenem may interact with other medicines, requiring avoidance or monitoring.

Major Interactions (Avoid): - Valproic acid: reduces plasma levels and may precipitate seizures. - Probenecid: decreases renal clearance, increasing meropenem exposure. - Loop diuretics: may enhance nephrotoxic potential.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity; monitor renal function. - NSAIDs: may impair renal clearance; observe kidney parameters. - Anticoagulants (e.g., warfarin): possible alteration of INR; check coagulation status regularly.

Frequently asked questions

What infections is Meropenem Anfarm used to treat?+
Meropenem Anfarm is indicated for severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired (nosocomial) pneumonia, bacterial meningitis, and severe sepsis or septic shock. It is administered intravenously in hospital settings where rapid, broad‑spectrum antibacterial activity is required.
How does meropenem work to fight bacteria?+
Meropenem belongs to the carbapenem class and works by binding to penicillin‑binding proteins on bacterial cell walls. This binding blocks the cross‑linking of peptidoglycan strands, weakening the wall and causing bacterial cell lysis. The result is a rapid, bactericidal effect against many Gram‑positive, Gram‑negative, and anaerobic organisms, including resistant strains.
What is the usual dose of Meropenem Anfarm?+
The dosing regimen for Meropenem Anfarm is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. Healthcare professionals calculate the appropriate intravenous dose and infusion rate for each individual patient.
Is Meropenem Anfarm safe to use during pregnancy or breastfeeding?+
The safety of Meropenem Anfarm in pregnancy and lactation has not been definitively established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.
How do I order Meropenem Anfarm from GNH USA?+
To place an order, submit an enquiry on the Meropenem Anfarm product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.
How does Meropenem compare with other carbapenems such as imipenem or ertapenem?+
Meropenem offers a broader spectrum against Pseudomonas aeruginosa and many resistant Gram‑negative organisms compared with imipenem, and it has a lower risk of seizures than imipenem. Unlike ertapenem, which lacks activity against Pseudomonas and Acinetobacter, meropenem retains potency against these pathogens, making it a preferred choice for severe, high‑risk infections.
What are the recommended storage conditions for Meropenem Anfarm?+
Meropenem Anfarm should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If the product is reconstituted, use it within the time frame specified in the package insert and maintain refrigeration until administration.
How is Meropenem Anfarm administered to patients?+
Meropenem Anfarm is supplied as a sterile powder for injection. After reconstitution with the appropriate diluent, it is administered intravenously, typically over a 15‑30 minute infusion. The exact infusion rate and dosing schedule are determined by the treating physician based on infection severity and patient-specific factors.
What are the most serious risks associated with Meropenem Anfarm?+
The most serious adverse events include seizures (especially in patients with renal impairment or pre‑existing CNS disorders), severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and significant neutropenia or leukopenia. Clinicians should monitor patients closely for neurological changes, rash, gastrointestinal symptoms, and blood count abnormalities.
Who should not receive Meropenem Anfarm?+
Meropenem Anfarm is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for individuals with a history of seizures, severe renal impairment without dose adjustment, or those receiving valproic acid, due to increased risk of neurotoxicity.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Meropenem Anhydrous
Route
Intravenous Use
Manufacturer
Anfarm Hellas Sa
Origin
EU

Related products

Agenor

Agenor

Meropenem Anhydrous

Medochemie Ltd.
EU
Agenorem

Agenorem

Meropenem Anhydrous

Medochemie Ltd.
EU
Archifar

Archifar

Meropenem Anhydrous

Medochemie Ltd.
EU
Archifar

Archifar

Meropenem Anhydrous

Medochemie Ltd.
EU